Outcome of patients with recurrent adult-type granulosa cell tumors - A Taiwanese Gynecologic Oncology Group study
Journal
Taiwanese Journal of Obstetrics and Gynecology
Journal Volume
253
Journal Issue
259
Pages
253-259
Date Issued
2015
Author(s)
Wang P.-H.
Sun H.-D.
Lin H.
Wang K.-L.
Liou W.-S.
Hung Y.-C.
Lu C.-H.
Lai H.-C.
Chang T.-C.
Yen M.-S.
Lai C.-H.
Yu M.-S.
Chou C.-Y.
Chang C.-L.
Huang K.-F.
Ho C.-M.
Chu T.-Y.
Wang P-H.
Liu F-S.
Kan Y.-Y.
Wu C.-H.
Taiwanese Gynecologic Oncology Group
Abstract
Objective: The aim of this study is to evaluate the long-term outcome of ovarian recurrent granulosa cell tumors (GCTs) in a large series of patients treated in Taiwanese Gynecologic Oncology Group (TGOG) centers and to define the prognostic parameters for survival. Materials and methods: A retrospective multi-institutional review of patients with recurrent ovarian GCTs treated in TGOG centers was conducted. The clinical and pathological characteristics, treatment, and outcomes of patients with ovarian recurrent GCTs were analyzed using Kaplan-Meier and Cox proportional hazards analyses to determine the predictors for survival. Results: A total of 44 patients from 16 medical centers were identified between January 1994 and December 2010. The median disease-free survival (DFS), postrecurrence survival, and overall survival (OS) were 61.5 months (range, 3.7-219.3 months), 55.8 months (range, 4.6-193.7 months), and 115.3 months (range, 17.2-390.6 months), respectively. In multivariate analysis, DFS (> 61.5 months versus ? 61.5 months, hazard ratio (HR) 0.15, 95% confidence interval (CI) 0.03-0.78, p = 0.024) at the initial operation after diagnosis of relapse was the only predictor that correlated with OS. Conclusion: DFS after the initial operation was the only important predictor for overall survival in patients with recurrent GCTs, regardless of treatment, suggesting that the natural behavior of the tumor is a critical factor for patients with recurrent GCTs. ? 2015.
SDGs
Other Subjects
bleomycin; cisplatin; doxorubicin; etoposide; vinblastine; antineoplastic agent; bleomycin; cisplatin; etoposide; adult; aged; Article; cancer combination chemotherapy; cancer mortality; cancer prognosis; cancer survival; clinical article; clinical feature; disease free survival; female; granulosa cell tumor; human; hysterectomy; multicenter study; outcome assessment; overall survival; retrospective study; salpingooophorectomy; survival prediction; tumor recurrence; adjuvant chemotherapy; adjuvant therapy; clinical trial; follow up; granulosa cell tumor; Kaplan Meier method; middle aged; Ovarian Neoplasms; pathology; Peritoneal Neoplasms; proportional hazards model; secondary; survival rate; Taiwan; tumor recurrence; young adult; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Granulosa Cell Tumor; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Taiwan; Young Adult
Type
journal article